If you want better sources: ---- Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving

If you want better sources: ---- Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. "This literature-based meta-analysis did not find evidence for the benefit of statin therapy on all-cause mortality in a high-risk primary prevention set-up." http://www.ncbi.nlm.nih.gov/pubmed/20585067 http://www.ncbi.nlm.nih.gov/pubmed/20585067 ---- Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database "Based on the 20% threshold for cardiovascular risk, for women the NNT with any statin to prevent one case of cardiovascular disease over five years was 37 (95% confidence interval 27 to 64) and for oesophageal cancer was 1266 (850 to 3460) and for men the respective values were 33 (24 to 57) and 1082 (711 to 2807). In women the NNH for an additional case of acute renal failure over five years was 434 (284 to 783), of moderate or severe myopathy was 259 (186 to 375), of moderate or severe liver dysfunction was 136 (109 to 175), and of cataract was 33 (28 to 38). Overall, the NNHs and NNTs for men were similar to those for women, except for myopathy where the NNH was 91 (74 to 112)." http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874131/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874131/ ---- Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. "The results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors." http://www.ncbi.nlm.nih.gov/pubmed/20585068 http://www.ncbi.nlm.nih.gov/pubmed/20585068 ---- Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. " Risk of statin-associated elevated liver enzymes or rhabdomyolysis is not related to the magnitude of LDL-C lowering. However, the risk of cancer is significantly associated with lower achieved LDL-C levels. These findings suggest that drug- and dose-specific effects are more important determinants of liver and muscle toxicity than magnitude of LDL-C lowering. Furthermore, the cardiovascular benefits of low achieved levels of LDL-C may in part be offset by an increased risk of cancer." http://www.ncbi.nlm.nih.gov/pubmed/17662392 http://www.ncbi.nlm.nih.gov/pubmed/17662392 ---- Statins and risk of polyneuropathy "Long-term exposure to statins may substantially increase the risk of polyneuropathy." http://www.neurology.org/cgi/content/abstract/58/9/1333 http://www.neurology.org/cgi/content/abstract/58/9/1333 ---- Relation between cholesterol levels and neuropsychiatric disorders " It is shown that low cholesterol levels in serum are associated and related to different neuropsychiatric disorders. Lowered cholesterol levels seem likely to be linked to higher rates of early death, suicide, aggressive and violent behaviour, personality disorders, and possibly depression, dementia and penal confinement among young males. Further studies are needed to confirm the evidence currently available and to relate more accurate diagnoses with hypocholesterolemia." http://www.ncbi.nlm.nih.gov/pubmed/19263395 http://www.ncbi.nlm.nih.gov/pubmed/19263395